A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

NCT04524871 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

518

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Liver Cancers

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab 15 mg/kg
DRUG: Tiragolumab
DRUG: Tocilizumab
DRUG: TPST-1120
DRUG: Tobemstomig 2100 mg
DRUG: Bevacizumab 10 mg/kg
DRUG: Tobemstomig 600 mg
DRUG: Tobemstomig 1200 mg
DRUG: ADG126
DRUG: IO-108 1800 mg
DRUG: NKT2152
DRUG: IO-108 1200 mg

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]